Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen (AMGN) stock slips as company posts mid-stage trial data for weight loss therapy MariTide. Rivals Eli Lilly (LLY) and ...

Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...